Dako inks companion diagnostics deal with Pfizer

Dako has signed a companion diagnostics deal with Pfizer--courtesy of Dako

Agilent Technologies' ($A) Dako unit has added Pfizer ($PFE) to its list of companion diagnostics partners, signing a deal that covers the research, development and commercialization of tests to match the drugmaker's pipeline treatments.

And that's about where the details stop. Neither company is disclosing financial details, and their joint statement makes no mention of which therapeutic areas the partnership will target. Dako didn't respond to a request for comment Tuesday.

In any case, the Pfizer deal is Dako's third Big Pharma team-up over the past year. Last month, Dako paired with Eli Lilly ($LLY) to develop diagnostics for the drugmaker's oncology platform, and, last year, it struck up a similar agreement with Amgen ($AMGN) on an investigational cancer drug.

"We are extremely excited to partner with Pfizer, a company with such a global presence and reputation for market leadership," Dako CEO Lars Holmkvist said in a statement. "This collaboration is testimony to the level of expertise and service Dako is committed to delivering to our partners in companion diagnostics."

Danish Dako was long a rising star in the diagnostics world, partnering with industry heavyweights like AstraZeneca ($AZN), Bristol-Myers Squibb ($BMY) and Quintiles. That was enough to attract Agilent, which paid $2.2 billion to acquire the company last spring.

- read Dako's statement

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.